Nu-Med Plus, Inc. reported a net loss of $56,182 for the fiscal year ending December 31, 2025, a decrease from the previous year's loss of $68,345. The company had no revenue during this period, consistent with its ongoing development stage. Operating expenses totaled $48,955, down from $63,331 in 2024, primarily due to reductions in various costs, including dues and subscriptions, filing fees, and professional fees. The company’s total assets decreased to $7,911 from $9,373 in the prior year, while total liabilities increased to $279,189 from $224,469, reflecting ongoing financial challenges.
In terms of strategic developments, Nu-Med has focused on the design and development of medical devices for nitric oxide delivery, including a hospital unit, a clinical unit, and a portable device. However, product development has been suspended due to a lack of funding, and the company is currently seeking a merger partner to facilitate further development. The company has two employees and relies heavily on its management team for operations, which raises concerns about its ability to execute its business plan effectively.
Operationally, Nu-Med has not yet established a customer base, as it has not received FDA approval for any of its products. The company has developed prototypes for its nitric oxide delivery systems but has not advanced to commercialization. The management anticipates that significant capital will be required to complete product development and testing, with projected costs for the upcoming year estimated at $1.25 million. Without additional funding, the company may face challenges in continuing operations.
Looking ahead, Nu-Med's management has expressed concerns about the company's ability to continue as a going concern, given its accumulated deficit and reliance on external financing. The company is actively seeking additional capital through equity sales and loans from shareholders to support its operations and product development efforts. The management's plans include a phased approach to capital raising, which they believe will help mitigate dilution for existing shareholders while progressing towards product commercialization.
Overall, Nu-Med Plus, Inc. remains in a precarious financial position, with no current revenue and significant operational hurdles. The company's future hinges on securing adequate funding and successfully navigating the regulatory landscape to bring its nitric oxide delivery devices to market.
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. develops medical devices utilizing nitric oxide for therapeutic and research applications. Its core products include nitric oxide generation systems and delivery devices for hospitals, clinics, and research labs. Focused on expanding nitric oxide's medical uses, the company aims to improve treatment costs and accessibility. Operating in the medical device sector, it targets healthcare providers and research institutions with innovative, technology-driven solutions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.